Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIS-FB-LRX in Geographic Atrophy Secondary to AMD
2020-005174-94Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- May 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in age-related macular degeneration (AMD) comparing IONIS-FB-LRX with Placebo (2 arms). Primary endpoint: Mean rate of growth in GA area. Started May 2021; status: completed.
02
Drugs
sefaxersen
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2020-005174-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005174-94.